USA flag logo/image

An Official Website of the United States Government

Enhancing the Vascularization Properties of Skin Tissue

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75836
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
AG026903
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Stratatech Corporation
505 S. Rosa Road, Suite 169 Madison, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Enhancing the Vascularization Properties of Skin Tissue
Agency: HHS
Contract: 1R43AG026903-01
Award Amount: $167,958.00
 

Abstract:

DESCRIPTION (provided by applicant): Cutaneous ulcers afflict approximately 4.5 million patients in the United States each year and it is estimated that 15% of older adults in the United States suffer from chronic, hard-to-heal skin wounds. Many of these wounds fail to heal, often resulting in severe complications including amputations and life-threatening infections. The healing of these wounds is often impaired by hypoxia, so strategies to enhance vascularization and simultaneously stimulate multiple repair processes have the potential to significantly improve the treatment and healing of chronic wounds. Stratatech Corporation is developing a portfolio of engineered skin tissue products to improve the management and healing of chronic skin wounds. While administration of individual angiogenic factors may stimulate some aspects of angiogenesis, the simultaneous expression of multiple factors is required to promote morphologically and functionally normal vessels. This Phase I proposal is designed to test the hypothesis that keratinocytes can be engineered to coordinately express elevated levels of multiple therapeutic factors. This will be accomplished by stably introducing a master regulator of hypoxia-induced wound healing responses into a proprietary keratinocyte cell source using non-viral vectors and characterizing the expression and secretion of biologically-active angiogenic factors. If successful, the proposed research will ultimately lead to the development and commercialization of improved treatments to promote the healing of chronic wounds and other severe skin defects.

Principal Investigator:

Allen R. Comer
6084412750
ACOMER@STRATATECHCORP.COM

Business Contact:

Robert Barnard
6084412756
RBARNARD@STRATATTECHORP.COM
Small Business Information at Submission:

Stratatech Corporation
505 South Rosa Road Suite 169 Madison, WI 53719

EIN/Tax ID: 392025292
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No